What is it about?
We report the case of a 38-year-old woman diagnosed with adenomyosis and administered low-dose oral contraceptives who subsequently developed cerebral venous and sinus thrombosis. After continuation of her symptoms of adenomyosis, she was treated with GnRHa draw-back therapy rather than total hysterectomy because she desired to preserve her uterus. To date, she has been successfully treated for 2.5 years with no complications.
Featured Image
Why is it important?
This case is important for two reasons: First, it emphasizes the need for gynecologists to be aware of the elevated risk of thrombosis, including cerebral thrombosis, in patients with adenomyosis. Second, it shows the successful use of GnRHa draw-back therapy for adenomyosis, even for a patient with cerebral venous and sinus thrombosis.
Perspectives
It can be an arbor of long-term conservative treatment options for uterine adenomyosis.
Mr Takashi Matsushima
Nippon Medical School Musashikosugi Hospital
Read the Original
This page is a summary of: Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use, Clinical and Experimental Obstetrics & Gynecology, February 2017, IMR Press,
DOI: 10.12891/ceog3214.2017.
You can read the full text:
Contributors
The following have contributed to this page
